Carolina Gomes da Silveira Cauduro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carolina Gomes da Silveira Cauduro has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ana Paula Franco Lambert
Pontifícia Universidade Católica do Rio Grande do Sul, Brazil
1 shared publication - André Poisl Fay
PUCRS School of Medicine, Porto Alegre, Brazil
1 shared publication Antonella Putignano
Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
1 shared publicationAntonia Lepida
Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
1 shared publicationAstrid Marot
Department of Gastroenterology and Hepatology, CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium
1 shared publicationBianca Albuquerque
1 shared publication
Latest Publications
- Open Access
- 17 May 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (8) , 100791
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications
- 17 May 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (8) , 100791
Open AccessA machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications
- 1 April 2017
- Published by Elsevier in Hand Surgery and Rehabilitation
- Vol. 36 (2) , 71-85
Nerve conduits for treating peripheral nerve injuries: A systematic literature review
- 1 April 2017
- Published by Elsevier in Hand Surgery and Rehabilitation
- Vol. 36 (2) , 71-85
Nerve conduits for treating peripheral nerve injuries: A systematic literature review
- 18 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 28 (1) , 191-192
Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma
Immune checkpoint blockade (ICB), including Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1, restores the effectiveness of T-cell responses overcoming tumor-adaptive mechanisms to escape immune surveillance. In different tumor types, high response rates have been seen with combination of these agents; however, dual ICB increases the risk of immune-related adverse events (irAE) [1].
- 18 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 28 (1) , 191-192
Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma
Immune checkpoint blockade (ICB), including Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1, restores the effectiveness of T-cell responses overcoming tumor-adaptive mechanisms to escape immune surveillance. In different tumor types, high response rates have been seen with combination of these agents; however, dual ICB increases the risk of immune-related adverse events (irAE) [1].
- Open Access
- 10 January 2016
- Published by Sciencedomain International in British Journal of Medicine and Medical Research
- Vol. 18 (10) , 1-9
It is Time for More Research into Umbilical Cord Stem Cells as a Potential Treatment in Neurological Diseases
Umbilical cord stem cells (UCSCs) from newborn individuals have been widely used to treat blood and immune disorders. In recent years, many public and private cord blood banks have preserved UCSCs in the hope of using them to cure diseases, especially neurological conditions. Preclinical studies showed UCSCs have considerable regenerative potential and early clinical investigations demonstrated they are safe and effective. Here, we discuss the characteristics and clinical application of UCSCs as a potential treatment for prevalent neurological disorders, based on published studies and ongoing trials registered in Clinicaltrials.gov. Despite the advantages of UCSCs compared to other stem cell sources, few published randomized and controlled clinical studies have investigated their therapeutic potential in neurological disorders, including cerebral palsy and spinal cord injury, with interesting results. Thus, there is an urgent need for more investigation, such as well-designed, phase II and III randomized and controlled clinical trials.
- 10 January 2016
- Published by Sciencedomain International in British Journal of Medicine and Medical Research
- Vol. 18 (10) , 1-9
Open AccessIt is Time for More Research into Umbilical Cord Stem Cells as a Potential Treatment in Neurological Diseases
Umbilical cord stem cells (UCSCs) from newborn individuals have been widely used to treat blood and immune disorders. In recent years, many public and private cord blood banks have preserved UCSCs in the hope of using them to cure diseases, especially neurological conditions. Preclinical studies showed UCSCs have considerable regenerative potential and early clinical investigations demonstrated they are safe and effective. Here, we discuss the characteristics and clinical application of UCSCs as a potential treatment for prevalent neurological disorders, based on published studies and ongoing trials registered in Clinicaltrials.gov. Despite the advantages of UCSCs compared to other stem cell sources, few published randomized and controlled clinical studies have investigated their therapeutic potential in neurological disorders, including cerebral palsy and spinal cord injury, with interesting results. Thus, there is an urgent need for more investigation, such as well-designed, phase II and III randomized and controlled clinical trials.